NCT03037840

Brief Summary

Studies have shown that tumor specific amplitude-modulated frequencies of radiofrequency electromagnetic fields that is associated with biofeedback upon exposure to in cancer patients. However, such discovery in other cancer patients are rare. And whether tumor specific frequencies can be found in Asian cancer patients remains unclear. The purpose of this study is to detect the tumor specific frequencies of Asian cancer patients in vivo.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2018

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 6, 2016

Completed
7 months until next milestone

First Posted

Study publicly available on registry

January 31, 2017

Completed
1.8 years until next milestone

Study Start

First participant enrolled

December 1, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2020

Completed
Last Updated

October 12, 2018

Status Verified

October 1, 2018

Enrollment Period

6 months

First QC Date

July 6, 2016

Last Update Submit

October 11, 2018

Conditions

Neoplasms

Keywords

RF EMFIn Vivotumor specific frequencies

Outcome Measures

Primary Outcomes (1)

  • Biofeedback response of cancer patients at the exposure of Low intensity amplitude-modulated radiofrequency electromagnetic fields

    within 20 min of exposure

Secondary Outcomes (1)

  • Representation of autonomous response during the exposure of tumor specific frequencies modutated RF eletromagnetic fields

    within 20 min of exposure

Study Arms (2)

cancer patients

Low intensity amplitude-modulated RF EMFs

Device: Low intensity amplitude-modulated RF EMFs

healthy participators

Low intensity amplitude-modulated RF EMFs

Device: Low intensity amplitude-modulated RF EMFs

Interventions

Low intensity amplitude-modulated RF EMFsDEVICE

Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW

Also known as: Low intensity AM RF EMFs
cancer patientshealthy participators

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. The patients who are diagnosed with cancer disease 2. Healthy participators

You may qualify if:

  • Clinical diagnosis of cancer Disease

You may not qualify if:

  • other patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14;28(1):51. doi: 10.1186/1756-9966-28-51.

    PMID: 19366446BACKGROUND

  • Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23;105(5):640-8. doi: 10.1038/bjc.2011.292. Epub 2011 Aug 9.

    PMID: 21829195BACKGROUND

  • Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1.

    PMID: 22134506BACKGROUND

  • Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177.

    PMID: 24206915BACKGROUND

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Xin Sherman Xuegang, professor

    School of Biomedical Engineering,Southern Medical University

    PRINCIPAL INVESTIGATOR

  • Cai Linbo, master

    Guangdong 999 Brain Hospital

    STUDY DIRECTOR

  • Zhu Xiaoxia, PhD

    Nanfang Hospital, Southern Medical University

    STUDY DIRECTOR

  • Liu Xiantang, bachelor

    The 157th Hospital of PLA

    STUDY DIRECTOR

Central Study Contacts

Xin Sherman Xuegang, professor

CONTACT

008613602733465xxg@smu.edu.cn

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 6, 2016

First Posted

January 31, 2017

Study Start

December 1, 2018

Primary Completion

June 1, 2019

Study Completion

June 1, 2020

Last Updated

October 12, 2018

Record last verified: 2018-10